key: cord-0896773-j14j37sg authors: Maródi, László title: A Rose Amongst the Thorns: the Mission of the J Project in a Conflictual World date: 2022-05-09 journal: J Clin Immunol DOI: 10.1007/s10875-022-01285-7 sha: 65370bc6cb91b58bbfe4a8cc427af3bdaebc1eb1 doc_id: 896773 cord_uid: j14j37sg nan of the JP is that we are still together and growing in terms of the area covered, the countries and centers included, and we are developing across existing differences of various kinds between the 32 countries now involved in the project [1] . We are not alone in this endeavor. Indeed, we collaborate closely with the European Society for Immunodeficiencies, the Jeffrey Modell Foundation, and pharmaceutical companies, which provide educational grants for the organization of JP meetings [2] . We are not immune from the problems of a lack of engagement with this wonderful joint project, albeit in only a few countries or a few centers in some countries. We continually try to persuade the less active centers to re-engage in the Project and to bring them back into the fold. We hope to convince them that the JP exists primarily to help those who are lagging behind, and that the reward for our efforts is the diagnosis and treatment of more and more patients throughout Central Europe and Eurasia, including, recently, in Siberia and the Far East of Russia [3, 4] . Advanced centers should be keen to find new ways to help the less developed centers and to raise the global level of patient management and understanding of the importance of IEI throughout medical fields. In a more global sense, the JP provides us with an excellent example of how to overcome differences and conflicts between countries and nations and to build collegiality and friendship through a focus on professional collaboration in our growing community, even during times of strife when tensions surround us. A prominent expression of our strength and reach is the increasing number of PID-focused meetings ( Fig. 1) , reflecting considerable ambition and enthusiasm and paving the way for improvements in the diagnosis and treatment of patients in our still largely neglected but rapidly developing field [5] . Rather, it may represent the devotion of leaders of JP centers in member countries to provide a better care for patients with PID. Over the past 2 years, however, the particular increase could be attributed to opening the scope of the JP to unique mechanisms of coronavirus infectious disease 2019 (COVID-19) in PID patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A large number of JP centers have joined forces with the COVID Human Genetic Effort program coordinated by the Rockefeller Uni-versity and the National Institute of Health to extend participation in the COVID-19 research to the area of the JP. b JP meetings organized in 25 countries in 2021. An outstanding number of JP events were organized in Russia having the largest population among countries involved in the JP in ECE. However, both Hungary (estimated population (ep), 9,6 million) and Ukraine (ep, 43 million) organized 5 meetings, whereas 4 meetings were organized both in Turkey (ep, 84 million) and in the Republic of Moldova (ep, 2,6 million) suggesting the lack of correlation between meeting number and country population. In 11 countries one JP event were reported and 7 countries had no meeting at all. These data suggest remarkable differences in ambition or interest of leaders of JP countries in the JP at least in the past year. It is also likely that the JP is only one of the PID-related activities in the countries that have joined the Project over the past 18 years The 10th anniversary of the world primary immunodeficiency week: A J Project celebration Project Study Group. Fifteen years of the J Project The J Daughter Siberia Project BCG Moreau vaccine safety profile and NK cells-double protection against disseminated BCG infection in retrospective study of BCG vaccination in 52 Polish children with severe combined immunodeficiency Lethal infectious diseases as inborn errors of immunity: Toward a synthesis of the germ and genetic theories Acknowledgements We thank the patients and parents of the patients